Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis | ||
By: GlobeNewswire - 03 Oct 2022 | Back to overview list |
|
Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT, SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company developing therapeutics for T cell-driven inflammatory diseases, today announced it will report topline results for its pivotal trial in China of lead candidate, CBP-201, in patients with moderate-to-severe atopic dermatitis (AD). Following the press release, the Company will host a webcast and conference call at 5:30 a.m. PDT to discuss these results. The news release will be posted to the investor relations section of Connect Biopharma’s website at: https://investors.connectbiopharm.com/investors.
About Connect Biopharma Holdings Limited IR/PR CONTACTS: |
||
|
||
Copyright 2022 GlobeNewswire | Back to overview list |